AIRGAS THERAP
GenericsAIRGAS THERAP is a generic drug manufacturer focused on Cardiovascular, Respiratory.
AIRGAS THERAP's Key Drugs
AIRGAS THERAP's core commercial portfolio centers on ULSPIRA, spanning Cardiovascular and Respiratory — its most strategically important drugs approved in the last 15 years.
AIRGAS THERAP's Recent FDA Approvals
New NDA/BLA approvals for AIRGAS THERAP over the last two years — novel drugs only, excluding generics and label supplements.
AIRGAS THERAP's Therapeutic Areas
AIRGAS THERAP's approved drugs and pipeline span 2 therapeutic areas, led by Cardiovascular and Respiratory, across 0 biologic and 0 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
AIRGAS THERAP's Top Competitors
AIRGAS THERAP's closest competitors by therapeutic-area and drug-target overlap include Novartis, Merck, and Bayer. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
AIRGAS THERAP Pipeline Snapshot
Active clinical trials for AIRGAS THERAP across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • ULSPIRA leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Cardiovascular pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 2023-07-27
- Latest
- 2023-07-27
- Applications
- 1